#China #Shanghai #Kexing Biopharm #Pharma Innovation #CPHI 2026

Kexing Biopharm's Presence at CPHI & PMEC China 2026

From June 16 to 18, 2026, Kexing Biopharm marked its participation at the CPHI & PMEC China event held at the Shanghai New International Expo Center. The company took this opportunity to showcase an impressive array of innovative drug pipelines as well as over 30 products geared towards international markets. This strategic move not only emphasized Kexing Biopharm's commitment to global healthcare but also earned them the prestigious 'RD Innovation Award' for their innovations in both development and international outreach.

Celebrating Innovations and Achievements

The diverse range of products displayed included developments in oncology, autoimmune diseases, and metabolic disorders. Among the notable products were widely recognized medications like albumin-bound Paclitaxel, Bevacizumab, Infliximab, Enzalutamid, and Liraglutid. These compounds sparked extensive discussions among industry experts, highlighting their potential to meet critical healthcare needs.

Kexing Biopharm also took pride in unveiling several globally innovative drug pipelines, such as GB18 for treating cancer cachexia and GB19/GB26 targeting systemic lupus erythematosus. Their focus on ophthalmological treatments was exemplified by GB10, while GB20/GB24 addressed autoimmune conditions. The progress seen with their Phase-III clinical trials, particularly the long-acting GC and GB05 (an interferon inhalation solution), further demonstrated their advancements in pharmaceutical research.

Recognition of Kexing Biopharm's relentless pursuit of innovation was reflected in receiving the FE Innovation Award. This accolade, decided by leading industry figures, recognizes excellence in pharmaceutical innovation, clinical implementation breakthroughs, and broader market impacts. It served as a motivator for the company to continue its cutting-edge R&D efforts, contributing significantly to the future of the biopharmaceutical landscape.

Networking and Strategic Discussions

The CPHI event offered a vital platform for the business development team at Kexing Biopharm to engage in high-profile forums and roundtable discussions focused on global expansion strategies in the pharmaceutical sector. By addressing key topics such as the international marketability of Chinese biopharmaceuticals, the team showcased the achievements of Kexing Biopharm while gleaning insights on optimizing their internationalization strategies and harnessing global market opportunities.

An exclusive gathering for clients and partners occurred on the evening of June 15, fostering deep discussions about market dynamics and future strategic collaborations. This interaction was not just an informal gathering but laid the groundwork for building mutual trust and establishing beneficial partnerships on future projects.

Continuing Future Endeavors

Kexing Biopharm recognizes the CPHI as a strategic platform to highlight its strengths and connect with the global pharmaceutical community. Looking ahead, the company is committed to expanding its international presence and collaborating with global partners to deliver high-quality products to a wider audience. Kexing Biopharm's dedication to innovation and international collaboration positions them for sustained success in the increasingly competitive pharmaceutical industry.